106 related articles for article (PubMed ID: 30660796)
1. Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History.
Dagogo-Jack I; Robinson H; Mino-Kenudson M; Farago AF; Kamesan V; Iafrate AJ; Shaw AT; Lennerz JK
J Thorac Oncol; 2019 May; 14(5):835-843. PubMed ID: 30660796
[TBL] [Abstract][Full Text] [Related]
2. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
3. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
[TBL] [Abstract][Full Text] [Related]
4. Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments.
Coquerelle S; Darlington M; Michel M; Durand M; Borget I; Baffert S; Marino P; Perrier L; Durand-Zaleski I;
Value Health; 2020 Jul; 23(7):898-906. PubMed ID: 32762992
[TBL] [Abstract][Full Text] [Related]
5. Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.
Zugazagoitia J; Rueda D; Carrizo N; Enguita AB; Gómez-Sánchez D; Díaz-Serrano A; Jiménez E; Mérida A; Calero R; Lujan R; De Miguel E; Gámez P; Díaz-Hellín V; Nuñez JA; Iglesias L; Ferrer I; Paz-Ares L; Ponce-Aix S
Clin Lung Cancer; 2018 Jan; 19(1):65-73.e7. PubMed ID: 28780976
[TBL] [Abstract][Full Text] [Related]
6. Clinical next-generation sequencing in patients with non-small cell lung cancer.
Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
[TBL] [Abstract][Full Text] [Related]
7. Integrating a Next Generation Sequencing Panel into Clinical Practice in Ovarian Cancer.
Lee YJ; Kim D; Kim HS; Na K; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
Yonsei Med J; 2019 Oct; 60(10):914-923. PubMed ID: 31538426
[TBL] [Abstract][Full Text] [Related]
8. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
9. Chromosomal microarray provides enhanced targetable gene aberration detection when paired with next generation sequencing panel in profiling lung and colorectal tumors.
Mukherjee S; Ma Z; Wheeler S; Sathanoori M; Coldren C; Prescott JL; Kozyr N; Bouzyk M; Correll M; Ho H; Chandra PK; Lennon PA
Cancer Genet; 2016 Apr; 209(4):119-29. PubMed ID: 26880400
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer.
Laufer-Geva S; Rozenblum AB; Twito T; Grinberg R; Dvir A; Soussan-Gutman L; Ilouze M; Roisman LC; Dudnik E; Zer A; Rotem O; Lanman RB; Peled N
J Thorac Oncol; 2018 Nov; 13(11):1705-1716. PubMed ID: 30121392
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Genomic Profiling of Malignant Effusions in Patients with Metastatic Lung Adenocarcinoma.
Yang SR; Lin CY; Stehr H; Long SR; Kong CS; Berry GJ; Zehnder JL; Kunder CA
J Mol Diagn; 2018 Mar; 20(2):184-194. PubMed ID: 29269277
[TBL] [Abstract][Full Text] [Related]
12. Clinical Utility of Rapid
Dagogo-Jack I; Azzolli CG; Fintelmann F; Mino-Kenudson M; Farago AF; Gainor JF; Jiang G; Piotrowska Z; Heist RS; Lennes IT; Temel JS; Mooradian MJ; Lin JJ; Digumarthy SR; Batten JM; Robinson H; Nose V; Rivera M; Nardi V; Dias-Santagata D; Le LP; Sequist LV; Pitman M; Shepard JO; Shaw AT; Iafrate AJ; Lennerz JK
JCO Precis Oncol; 2018; 2018():. PubMed ID: 30370396
[TBL] [Abstract][Full Text] [Related]
13. Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer.
Takeda M; Sakai K; Terashima M; Kaneda H; Hayashi H; Tanaka K; Okamoto K; Takahama T; Yoshida T; Iwasa T; Shimizu T; Nonagase Y; Kudo K; Tomida S; Mitsudomi T; Saigo K; Ito A; Nakagawa K; Nishio K
Ann Oncol; 2015 Dec; 26(12):2477-82. PubMed ID: 26420428
[TBL] [Abstract][Full Text] [Related]
14. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
[TBL] [Abstract][Full Text] [Related]
15. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.
Mantripragada KC; Olszewski AJ; Schumacher A; Perez K; Birnbaum A; Reagan JL; Mega A; Khurshid H; Bartley C; Lombardo A; Rossiter R; Papa A; Bakalarski P; Safran H
J Oncol Pract; 2016 Apr; 12(4):e396-404. PubMed ID: 26907448
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
17. Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences.
Cho M; Ahn S; Hong M; Bang H; Van Vrancken M; Kim S; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Sun JM; Lee SH; Ahn MJ; Park K; Kim DH; Lee S; Park W; Kim KM
Oncotarget; 2017 Jun; 8(26):42478-42486. PubMed ID: 28477007
[TBL] [Abstract][Full Text] [Related]
18. Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy.
Garcia-Pardo M; Czarnecka K; Law JH; Salvarrey A; Fernandes R; Fan J; Corke L; Waddell TK; Yasufuku K; Donahoe LL; Pierre A; Le LW; Ghumman N; Liu G; Shepherd FA; Bradbury P; Sacher A; Stockley T; Pal P; Rogalla P; Tsao MS; Leighl NB
Ther Adv Med Oncol; 2022; 14():17588359221126151. PubMed ID: 36158638
[TBL] [Abstract][Full Text] [Related]
19. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
20. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
Flaherty KT; Gray RJ; Chen AP; Li S; McShane LM; Patton D; Hamilton SR; Williams PM; Iafrate AJ; Sklar J; Mitchell EP; Harris LN; Takebe N; Sims DJ; Coffey B; Fu T; Routbort M; Zwiebel JA; Rubinstein LV; Little RF; Arteaga CL; Comis R; Abrams JS; O'Dwyer PJ; Conley BA;
J Clin Oncol; 2020 Nov; 38(33):3883-3894. PubMed ID: 33048619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
